NeoGenomics (NASDAQ:NEO) reported quarterly earnings results on February 17, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $0.06, beating the consensus estimate of $0.01 by $0.05 per share. Revenue came in at $190.2M, beating the estimate of $188.4M.
NeoGenomics's stock moved following the earnings release. The stock currently trades at $11.01 with a market capitalization of $300.9M.
